TY - JOUR
T1 - Metabolomics profiling of visceral and abdominal subcutaneous adipose tissue in colorectal cancer patients
T2 - results from the ColoCare study
AU - Ose, Jennifer
AU - Holowatyj, Andreana N.
AU - Nattenmüller, Johanna
AU - Gigic, Biljana
AU - Lin, Tengda
AU - Himbert, Caroline
AU - Habermann, Nina
AU - Achaintre, David
AU - Scalbert, Augustin
AU - Keski-Rahkonen, Pekka
AU - Böhm, Jürgen
AU - Schrotz-King, Petra
AU - Schneider, Martin
AU - Ulrich, Alexis
AU - Kampman, Ellen
AU - Weijenberg, Matty
AU - Gsur, Andrea
AU - Ueland, Per Magne
AU - Kauczor, Hans Ulrich
AU - Ulrich, Cornelia M.
PY - 2020/8
Y1 - 2020/8
N2 - Purpose: Underlying mechanisms of the relationship between body fatness and colorectal cancer remain unclear. This study investigated associations of circulating metabolites with visceral (VFA), abdominal subcutaneous (SFA), and total fat area (TFA) in colorectal cancer patients. Methods: Pre-surgery plasma samples from 212 patients (stage I–IV) from the ColoCare Study were used to perform targeted metabolomics. VFA, SFA, and TFA were quantified by computed tomography scans. Partial correlation and linear regression analyses of VFA, SFA, and TFA with metabolites were computed and corrected for multiple testing. Cox proportional hazards were used to assess 2-year survival. Results: In patients with metastatic tumors, SFA and TFA were statistically significantly inversely associated with 16 glycerophospholipids (SFA: pFDR range 0.017–0.049; TFA: pFDR range 0.029–0.048), while VFA was not. Doubling of ten of the aforementioned glycerophospholipids was associated with increased risk of death in patients with metastatic tumors, but not in patients with non-metastatic tumors (phet range: 0.00044–0.049). Doubling of PC ae C34:0 was associated with ninefold increased risk of death in metastatic tumors (Hazard Ratio [HR], 9.05; 95% confidence interval [CI] 2.17–37.80); an inverse association was observed in non-metastatic tumors (HR 0.17; 95% CI 0.04–0.87; phet = 0.00044). Conclusion: These data provide initial evidence that glycerophospholipids in metastatic colorectal cancer are uniquely associated with subcutaneous adiposity, and may impact overall survival.
AB - Purpose: Underlying mechanisms of the relationship between body fatness and colorectal cancer remain unclear. This study investigated associations of circulating metabolites with visceral (VFA), abdominal subcutaneous (SFA), and total fat area (TFA) in colorectal cancer patients. Methods: Pre-surgery plasma samples from 212 patients (stage I–IV) from the ColoCare Study were used to perform targeted metabolomics. VFA, SFA, and TFA were quantified by computed tomography scans. Partial correlation and linear regression analyses of VFA, SFA, and TFA with metabolites were computed and corrected for multiple testing. Cox proportional hazards were used to assess 2-year survival. Results: In patients with metastatic tumors, SFA and TFA were statistically significantly inversely associated with 16 glycerophospholipids (SFA: pFDR range 0.017–0.049; TFA: pFDR range 0.029–0.048), while VFA was not. Doubling of ten of the aforementioned glycerophospholipids was associated with increased risk of death in patients with metastatic tumors, but not in patients with non-metastatic tumors (phet range: 0.00044–0.049). Doubling of PC ae C34:0 was associated with ninefold increased risk of death in metastatic tumors (Hazard Ratio [HR], 9.05; 95% confidence interval [CI] 2.17–37.80); an inverse association was observed in non-metastatic tumors (HR 0.17; 95% CI 0.04–0.87; phet = 0.00044). Conclusion: These data provide initial evidence that glycerophospholipids in metastatic colorectal cancer are uniquely associated with subcutaneous adiposity, and may impact overall survival.
KW - Adipose tissue
KW - Colorectal cancer
KW - Glycerophospholipids
KW - Survival
U2 - 10.1007/s10552-020-01312-1
DO - 10.1007/s10552-020-01312-1
M3 - Article
C2 - 32430684
AN - SCOPUS:85085057178
SN - 0957-5243
VL - 31
SP - 723
EP - 735
JO - Cancer Causes and Control
JF - Cancer Causes and Control
ER -
